Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data
F Martora, M Scalvenzi, T Battista… - Clinical, Cosmetic …, 2023 - Taylor & Francis
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …
[HTML][HTML] Management of Psoriasis Patients with Serious Infectious Diseases
M Megna, G Lauletta, N Tommasino, A Salsano… - Advances in …, 2024 - Springer
The management of patients affected by moderate-to-severe psoriasis may be challenging,
in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C …
in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C …
Biologics for the management of erythrodermic psoriasis: an updated review
L Potestio, E Camela, S Cacciapuoti… - Clinical, Cosmetic …, 2023 - Taylor & Francis
Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of
cases), characterized by generalized scaling and erythema affecting more than 90% of body …
cases), characterized by generalized scaling and erythema affecting more than 90% of body …